Variable | n (%) | Recurrence-free survival | Overall survival | ||||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
Age, as continuous variable | 5181 | 1.001 (0.992 to 1.010) | 0.82 | 1.007 (0.997 to 1.018) | 0.19 | ||||
FIGO stage | |||||||||
IA2 | 62 (1.2) | Reference | Reference | ||||||
IB1 | 2482 (47.9) | Broad | 0.75 | Broad | 0.82 | ||||
IB2 | 388 (7.5) | Broad | 0.73 | Broad | 0.81 | ||||
IIA1 | 1598 (30.8) | Broad | 0.73 | Broad | 0.80 | ||||
IIA2 | 651 (12.6) | Broad | 0.73 | Broad | 0.80 | ||||
Histopathologic type | |||||||||
SCC | 4510 (87.0) | Reference | Reference | ||||||
AC | 488 (9.4) | 2.594 (2.030 to 3.316) | <0.001* | Reference | 2.976 (2.226 to 3.977) | <0.001* | Reference | ||
ASC | 183 (3.5) | 2.105 (1.517 to 2.920) | <0.001* | 0.811 (0.550 to 1.197) | 0.29 | 2.295 (1.579 to 3.338) | <0.001* | 0.771 (0.492 to 1.209) | 0.26 |
Tumor size (cm), as continuous variable | 5181 | 1.105 (1.043 to 1.171) | 0.001* | 1.121 (1.047 to 1.200) | 0.001* | ||||
Depth of stromal invasion | |||||||||
≤1/3 | 1484 (30.6) | Reference | Reference | ||||||
>1/3 and ≤2/3 | 1640 (33.8) | 1.570 (1.163 to 2.121) | 0.003* | 1.683 (1.135 to 2.495) | 0.01* | ||||
>2/3 | 1729 (35.6) | 1.963 (1.433 to 2.689) | <0.001* | 2.335 (1.558 to 3.498) | <0.001* | ||||
Lymphovascular space invasion | |||||||||
No | 3006 (62.9) | Reference | Reference | ||||||
Yes | 1770 (37.1) | 2.203 (1.806 to 2.688) | <0.001* | 2.436 (1.909 to 3.109) | <0.001* | ||||
Peripheral nerve infiltration | |||||||||
No | 4274 (91.6) | Reference | Reference | ||||||
Yes | 393 (8.4) | 1.156 (0.906 to 1.474) | 0.243 | 1.252 (0.947 to 1.656) | 0.11 | ||||
Parametrial invasion | |||||||||
No | 4457 (91.7) | Reference | Reference | ||||||
Yes | 401 (8.3) | 1.951 (1.577 to 2.415) | <0.001* | 1.792 (1.395 to 2.302) | <0.001* | ||||
Vaginal margin involvement | |||||||||
No | 4764 (98.8) | Reference | Reference | ||||||
Yes | 58 (1.2) | 2.179 (1.352 to 3.513) | 0.001* | 1.956 (1.090 to 3.511) | 0.03* | ||||
Pelvic lymph node metastasis | |||||||||
No | 3761 (76.6) | Reference | Reference | ||||||
Yes | 1149 (23.4) | 1.422 (1.163 to 1.738) | 0.001* | 1.523 (1.199 to 1.934) | 0.001* | ||||
Para-aortic lymph node metastasis | |||||||||
No | 640 (85.4) | Reference | Reference | ||||||
Yes | 109 (14.6) | 1.685 (1.163 to 2.441) | 0.006* | 1.585 (1.033 to 2.433) | 0.04* | ||||
Adjuvant treatment | |||||||||
No | 1714 (35.5) | Reference | Reference | ||||||
Chemotherapy | 535 (11.1) | 0.807 (0.585 to 1.113) | 0.19 | 0.792 (0.529 to 1.187) | 0.26 | ||||
Radiotherapy | 929 (19.3) | 0.822 (0.621 to 1.088) | 0.17 | 0.884 (0.630 to 1.241) | 0.48 | ||||
Concurrent chemoradiotherapy | 1646 (34.1) | 0.540 (0.411 to 0.709) | <0.001* | 0.529 (0.379 to 0.738) | <0.001* |
*P<0.05.
AC, adenocarcinoma; ASC, adenosquamous carcinoma; CI, confidence interval;FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; SCC, squamous cell carcinoma.